WHO Sounds Concern Over Critical Shortage of Obesity Injections
Less than a tenth of patients who could benefit from weight-loss injections including Wegovy can access them, warns the WHO as it publishes its inaugural guidance on the medications.
Considering more than one billion individuals worldwide currently obese, it is urging more widespread and fairer availability to this class of drugs.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our latest guidelines affirms that obesity is a chronic disease that can be addressed with holistic and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are key hurdles to broad access to the jabs that can aid individuals in losing substantial weight, explains the agency.
Skinny Jab Scarcity
Even under the current most favorable scenario, the production of such drugs could only cover about 100 million people – less than 10% of eligible patients, as stated by the health organization.
The recommendation encourages governments and firms to widen access, by approaches like voluntary licensing.
The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Injections Function
GLP-1 drugs imitate a biological compound to reduce digestion speed, curb appetite and increase satiety so individuals reduce food intake.
Patients usually begin shedding pounds within a few weeks of starting on the weekly injections.
Evidence points to patients may see weight return within a year of discontinuing the treatment, as their typical hunger resume.
Being carrying excess weight elevates your risk for contracting health problems, including diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity concerns individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
